Interventional Tumor Ablation Global Market Report 2025

The interventional tumor ablation market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth during the forecast period can be attributed to the rising incidence of soft tissue and metastatic tumors, an increasing focus on personalized cancer treatment strategies, growing demand for non-surgical tumor treatment options, a shift toward cost-effective tumor therapies, and an expanding pipeline of advanced ablation devices. Key trends expected in the forecast period include the development of combination therapies, the creation of hybrid ablation techniques, the integration of ablation with data analytics, innovations in tumor-specific nano-ablation, and advancements in ablation system technologies.

The increasing prevalence of cancer is expected to significantly boost the growth of the interventional tumor ablation market in the near future. Cancer, a group of diseases defined by the uncontrolled proliferation and spread of abnormal cells in the body, can invade surrounding tissues and potentially metastasize through the blood and lymphatic systems. The growing number of cancer cases is largely attributed to lifestyle and environmental factors such as smoking, poor diet, obesity, and exposure to carcinogens. Interventional tumor ablation improves cancer treatment by offering minimally invasive techniques, providing patients with an alternative to surgery. These methods shorten treatment time and recovery periods by allowing precise destruction of tumors, which improves patient outcomes and overall quality of life. For example, according to a July 2024 report from the Australian Institute of Health and Welfare, the number of cancer diagnoses in Australia increased to 160,570 in 2022, marking a rise of 3,789 cases from 156,781 in 2021. This growing cancer incidence is driving the expansion of the interventional tumor ablation market.

Leading companies in the interventional tumor ablation market are focusing on developing advanced technological solutions, such as the BioTrace software suite, to improve the precision and effectiveness of tumor ablation procedures. BioTrace software suites are integrated tools designed to track, manage, and analyze biological data, particularly in healthcare and research environments. For example, in July 2024, TechsoMed Medical Technologies Ltd., an Israel-based medical device company, introduced the BioTraceIO Vision and BioTraceIO Precision software suites, aimed at enhancing image-guided liver tumor ablation therapy. BioTraceIO Vision incorporates artificial intelligence (AI)-powered tools for personalized treatment planning and assessment, using standard medical imaging to boost the accuracy and efficiency of liver tumor ablation procedures. BioTraceIO Precision, on the other hand, provides real-time ultrasound-based visualization and predictive mapping of the ablation zone during and after the procedure, helping clinicians evaluate tissue damage and treatment outcomes with high correlation to 24-hour post-ablation CT scans.

In February 2024, Immunophotonics Inc., a US-based biotechnology company, formed a partnership with AngioDynamics Inc. This collaboration aims to combine Immunophotonics’ leading immunotherapy asset, IP-001, with AngioDynamics’ ablation devices to explore the potential of combining ablation with immunotherapy in treating solid tumor cancers. AngioDynamics Inc., a US-based medical device company, offers microwave and radiofrequency ablation technologies for minimally invasive cancer treatment.

Major players in the interventional tumor ablation market are Johnson And Johnson, EDAP TMS S.A., Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Hologic Inc., Elekta, Conmed Corporation, Bioventus Inc., AtriCure, AngioDynamics Inc., Mermaid Medical Group A/S, InSightec, Cascination AG, H.S. Hospital Service S.p.A, Theraclion, IceCure Medical Ltd.

North America was the largest region in the interventional tumor ablation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interventional tumor ablation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the interventional tumor ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interventional tumor ablation market consists of revenues earned by entities by providing services such as electroporation, tumor biopsy services, thermal ablation monitoring, and post-ablation follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional tumor ablation market also includes sales of radiofrequency ablation (RFA) generators, microwave ablation (MWA) systems, cryoablation probes, laser fibers and electrode needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Interventional tumor ablation is a minimally invasive procedure that utilizes image-guided techniques to target and destroy cancerous or benign tumors without the need for open surgery. It uses thermal or non-thermal energy to eliminate tumor cells while minimizing damage to surrounding healthy tissue. This procedure is often employed when surgery is not viable or as an alternative to traditional treatments.

The main product types in interventional tumor ablation include open surgery, minimally invasive surgery, and image-guided interventions. Open surgery involves making an incision in the body to access and treat the affected area, typically using scalpels and other instruments. Key technologies in this field include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, and high-intensity focused ultrasound (HIFU). Device types used in these procedures include ablation systems, consumables, support devices, and imaging systems. Tumor ablation is frequently applied to liver, kidney, lung, and bone tumors. The end users of these technologies range from hospitals and specialized cancer treatment centers to ambulatory surgical centers and research institutes.

The interventional tumor ablation market research report is one of a series of new reports that provides interventional tumor ablation market statistics, including the interventional tumor ablation industry's global market size, regional shares, competitors with the interventional tumor ablation market share, detailed interventional tumor ablation market segments, market trends and opportunities, and any further data you may need to thrive in the interventional tumor ablation market. This interventional tumor ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interventional tumor ablation market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the increasing prevalence of liver and kidney cancers, greater awareness of minimally invasive cancer treatments, enhanced availability of diagnostic imaging, a growing geriatric population more susceptible to tumors, and a rising preference for outpatient procedures.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.